Regeneron (NASDAQ:REGN) Downgraded by Guggenheim

Galtero Lara
May 16, 2018

Regeneron Pharmaceuticals Inc. had 126 analyst reports since July 28, 2015 according to SRatingsIntel. Calamos Wealth Mgmt Limited Liability stated it has 0.1% in Regeneron Pharmaceuticals, Inc. (NASDAQ:SNES) hit a new 52-week low and has $0.38 target or 8.00% below today's $0.41 share price. It also reduced its holding in Hdfc Bank (NYSE:HDB) by 307,105 shares in the quarter, leaving it with 1.16M shares, and cut its stake in Alexion Pharmaceuticals (NASDAQ:ALXN). BTIM Corp. boosted its stake in shares of Regeneron by 14.3% during the 4th quarter. Moreover, Amer Gp Incorporated has 0.04% invested in Regeneron Pharmaceuticals, Inc. Piper Jaffray maintained the shares of REGN in report on Thursday, January 18 with "Buy" rating. Parametric Portfolio Associates Lc owns 186,635 shares or 0.07% of their U.S. portfolio. Greenleaf Trust holds 43 shares.

Price earnings ratio (P/E) ratio of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). X Limited Liability has invested 0.02% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Oppenheimer Asset Inc owns 10,609 shares for 0.13% of their portfolio. M&T Bankshares reported 15,227 shares. State Of Alaska Department Of Revenue reported 9,310 shares stake. Bokf Na holds 0.08% or 7,652 shares in its portfolio. (NASDAQ:REGN). Ww owns 4.81 million shares. SING GEORGE L sold $5.72 million worth of stock. Meeder Asset has 0.05% invested in Regeneron Pharmaceuticals, Inc. The 7 months bearish chart indicates high risk for the $6.78M company. If the $286.74 price target is reached, the company will be worth $1.63B less.

Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. The rating was upgraded by Zacks to "Hold" on Tuesday, August 11. The average rise is 32% and the decline is 15%. BMO Capital Markets has "Market Perform" rating and $105 target. There is no guarantee that when share prices reach a 52 week low, the stock will begin to trade higher - it could break down to an even lower level. About 1.09M shares traded or 15.45% up from the average. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 14.19% since May 13, 2017 and is downtrending. It has underperformed by 25.74% the S&P500. The stock of Regeneron Pharmaceuticals, Inc. Goldman Sachs maintained the stock with "Buy" rating in Thursday, January 19 report. The institutional investor held 48,259 shares of the prepackaged software company at the end of 2017Q4, valued at $5.42 million, up from 38,809 at the end of the previous reported quarter. They analyze the different factor and after that analysis they issue rating regarding stock whether it is time to buy the stock or sell the stock or even hold the stock based on analyzing factors. Therefore 57% are positive. Regeneron Pharmaceuticals, Inc.'s Return on Equity (ROE) is 23.50%, measure their profitability and reveals how much profit they generate with the money their shareholders. Finally, SunTrust Banks decreased their price target on Regeneron to $344.00 and set a "hold" rating for the company in a research report on Friday, May 4th. (NASDAQ:REGN) earned "Hold" rating by Jefferies on Thursday, February 8. The stock was sold at an average price of $285.29, for a total transaction of $1,997,030.00. As per Friday, July 14, the company rating was downgraded by Credit Suisse. Leerink Swann has "Outperform" rating and $502 target. The firm has "Market Perform" rating by Raymond James given on Monday, April 9. As per Wednesday, December 13, the company rating was maintained by RBC Capital Markets. The firm has "Equal-Weight" rating by Morgan Stanley given on Friday, February 9.

More news: Antonio Mohamed es una opción para el próximo ciclo mundialista de Honduras

More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: and their article: "Regeneron Pharmaceuticals: Sequencing Its Way to +30% Upside" published on May 03, 2018 as well as's news article titled: "Why Regeneron Has 30 Percent Upside" with publication date: May 07, 2018.

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company has market cap of $6.78 million. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It has a 29.68 P/E ratio. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Otros informes por

Discuta este artículo